Exagen Inc. to Participate in the 31st Annual Piper Jaffray Healthcare Conference on December 5, 2019
November 20 2019 - 4:15AM
Exagen Inc. (Nasdaq: XGN), an organization dedicated to
transforming the care continuum for patients suffering from
debilitating and chronic autoimmune diseases by enabling timely
differential diagnosis and optimizing therapeutic intervention,
today announced that Ron Rocca, CEO of Exagen, will be
participating in the 31st Annual Piper Jaffray Healthcare
Conference on Thursday, December 5 in New York City. Mr. Rocca’s
presentation will take place at 11:10 a.m.
A live audio webcast of the Piper Jaffray presentation will be
available online from the investor relations section of the Exagen
website at https://investors.exagen.com/ or through the following
link:
https://event.webcasts.com/starthere.jsp?ei=1273375&tp_key=2d415e377a
About Exagen Inc.
Exagen is dedicated to transforming the care continuum for
patients suffering from debilitating and chronic autoimmune
diseases by enabling timely differential diagnosis and optimizing
therapeutic intervention. Exagen has developed and is
commercializing a portfolio of innovative testing products under
its AVISE® brand, several of which are based on our proprietary
Cell-Bound Complement Activation Products, or CB-CAPs, technology.
Exagen’s goal is to enable rheumatologists to improve care for
patients through the differential diagnosis, prognosis and
monitoring of complex autoimmune and autoimmune-related diseases,
including SLE and rheumatoid arthritis.
CONTACTS:
InvestorsWestwicke Partners Mike
CavanaughMike.Cavanaugh@westwicke.com646.677.1838
CompanyExagen Inc. Kamal
AdawiKAdawi@exagen.com760.477.5514
Exagen (NASDAQ:XGN)
Historical Stock Chart
From Apr 2024 to May 2024
Exagen (NASDAQ:XGN)
Historical Stock Chart
From May 2023 to May 2024